Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

Key facts

Sponsor

Xiamen Amoytop Biotech Co., Ltd.

Principal Investigator

Lei Zhang

Chinese Academy of Medical Sciences

Intervention

Peginterferon α-2b injection(drug)

Enrollment

27 target

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (8)

• Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing, China
• Peking University People's Hospital, Beijing, China
• Union Hospital affiliated to Fujian Medical University, Fujian, China
• Nanfang Hospital, Southern Medical University, Guangzhou, China
• Harbin First Hospital, Harbin, China
• Henan Cancer Hospital, Henan, China
• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
• The First Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07469891
  A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
  Prelude Therapeutics
• RECRUITINGNCT06976918
  Registry Platform Myelofibrosis and Anemia
  iOMEDICO AG
• RECRUITINGNCT07203768
  A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
  FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
• RECRUITINGPHASE2NCT06517875
  Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
  GlaxoSmithKline
• RECRUITINGNANCT06734637
  Efficacy and Safety of Peginterferon in ET and PV.
  Zhenya Hong
• RECRUITINGPHASE1NCT06343805
  A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
  Ajax Therapeutics, Inc.
• RECRUITINGPHASE2NCT06541249
  MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
  Icahn School of Medicine at Mount Sinai
• RECRUITINGPHASE1, PHASE2NCT06327100
  Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
  M.D. Anderson Cancer Center

See all trials for Essential thrombocythemia →